NP mentioned that leronlimab will be cost-free for

NP mentioned that leronlimab will be cost-free for the first 50 or so patients, but it seems it may take more patients than that to prove if leronlimab works to fight the corona virus. Right now about 1 in every 40 are dying from the virus. So, only 50 patients wouldn’t be enough to definitively demonstrate that it’s reducing mortality, although if severity of symptoms or symptoms in general were reduced, that would be a bonus. Maybe 200 patients would be more accurate? One thing for sure there isn’t a shortage of patients for the trial, CYDY just needs to get the drug to them. The variety of patients is important too because we don’t want the 50 leronlimab doses given to the patient population that has the highest mortality rate (typically the very young, the very old, and those in between with comorbidities. I’m confident Dr. Patterson is working on the design with the Chinese company to avoid these issues.

I’m assuming CYDY and this Chinese company are mainly looking to reduce the rate of death and are less concerned at this time about reducing symptoms and the length of the illness (that’s basically what Tamiflu does).